Literature DB >> 32464163

The risk for developing a secondary cancer after breast radiation therapy: Comparison of photon and proton techniques.

Harald Paganetti1, Nicolas Depauw2, Andrew Johnson3, Rachel Beth Forman3, Jackson Lau3, Rachel Jimenez2.   

Abstract

BACKGROUND AND
PURPOSE: To compare secondary malignancy risks of modern proton and photon therapy techniques for locally advanced breast cancer. METHODS AND MATERIALS: We utilized dosimetric data from 34 [10 photon-VMAT, 10 photon-3DCRT, 14 pencil beam scanning proton (PBS)] breast cancer patients who received comprehensive nodal irradiation. Employing a model based on organ equivalent dose to account for both inhomogeneous organ dose distributions and non-linear functional dose relationships, we estimated excess absolute risk, excess relative risk, and lifetime attributable risk (LAR) for secondary malignancies. The model uses dose distribution, number of fractions, age at exposure, attained age, the linear-quadratic dose response relationship for cell survival, repopulation factor, as well as gender specific age dependencies, and initial slopes of dose response curves.
RESULTS: The LAR for carcinoma at age 70 was estimated to be up to 3.64% for esophagus with an advantage of 3DCRT over PBS and VMAT. For the ipsilateral lung, risks were lowest for PBS (up to 5.56%), followed by 3DCRT (up to 6.54%) and VMAT (up to 7.7%). For the contralateral lung, there is a clear advantage of 3DCRT and PBS techniques (risk <0.86%) over VMAT (up to 4.4%). The risk for the contralateral breast is negligible for 3DCRT and PBS but was estimated as up to 1.2% for VMAT. Risks for the thyroid are overall negligible. Independently performed comparative treatment plans on 10 patients revealed that the risk for the contralateral lung and breast using VMAT can be more than an order of magnitude higher compared to PBS. Sarcoma risks were estimated as well showing similar trends but were overall lower compared to carcinoma.
CONCLUSION: Conventional (3DCRT) techniques led to the lowest estimated risks of, thyroid and esophageal secondary cancers while PBS demonstrated a benefit for secondary lung and contralateral breast cancer risks, with the highest risks overall associated with VMAT techniques.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Outcome modelling; Secondary malignancies

Mesh:

Substances:

Year:  2020        PMID: 32464163     DOI: 10.1016/j.radonc.2020.05.035

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

1.  Dosimetric Comparison of Radiation Techniques for Comprehensive Regional Nodal Radiation Therapy for Left-Sided Breast Cancer: A Treatment Planning Study.

Authors:  Heejoo Ko; Jee Suk Chang; Jin Young Moon; Won Hee Lee; Chirag Shah; Jin Sup Andy Shim; Min Cheol Han; Jong Geol Baek; Ryeong Hwang Park; Yong Bae Kim; Jin Sung Kim
Journal:  Front Oncol       Date:  2021-04-12       Impact factor: 6.244

Review 2.  Particle Therapy for Breast Cancer.

Authors:  Roman O Kowalchuk; Kimberly S Corbin; Rachel B Jimenez
Journal:  Cancers (Basel)       Date:  2022-02-20       Impact factor: 6.639

Review 3.  Proton Therapy for Breast Cancer: A Consensus Statement From the Particle Therapy Cooperative Group Breast Cancer Subcommittee.

Authors:  Robert W Mutter; J Isabelle Choi; Rachel B Jimenez; Youlia M Kirova; Marcio Fagundes; Bruce G Haffty; Richard A Amos; Julie A Bradley; Peter Y Chen; Xuanfeng Ding; Antoinette M Carr; Leslie M Taylor; Mark Pankuch; Raymond B Mailhot Vega; Alice Y Ho; Petra Witt Nyström; Lisa A McGee; James J Urbanic; Oren Cahlon; John H Maduro; Shannon M MacDonald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-05-25       Impact factor: 8.013

4.  Proton pencil beam scanning reduces secondary cancer risk in breast cancer patients with internal mammary chain involvement compared to photon radiotherapy.

Authors:  Giorgio Cartechini; Francesco Fracchiolla; Loris Menegotti; Emanuele Scifoni; Chiara La Tessa; Marco Schwarz; Paolo Farace; Francesco Tommasino
Journal:  Radiat Oncol       Date:  2020-10-02       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.